OakChart

Treace Medical Concepts Inc

TMCIHealthcare·Medical Devices·USA·Small·NASD·Nov 11 • 3:59 PM ET

5.06+0.18 (3.69%)
2026-11-12 02:29 CET
Market cap
319.93 USD m
Revenue, TTM
203.35 USD m
Net income, TTM
-55.79 USD m
Free cash flow, TTM
-18.58 USD m
EPS diluted, TTM
-0.86
P/E
-
Compare

Price

TMCI against its 20, 50 and 200-day averages
2050200beat
2.003.004.005.003.5M7.0MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26TMCIclose 5.0620-day 4.4050-day 4.41200-day 3.315.0652w high

7.0% under the 52-week high of 5.44 on 11 Nov 2026. 52-week low 1.17 on 30 Mar 2026. Last 15 sessions, 59.1% high to low

Volume 2.10× normal · the line is the 50-bar volume average

Profile

TMCI
52-week range, 95% of the way up
1.175.25

Treace Medical Concepts, Inc. engages in the designing, manufacturing, and marketing of orthopedic medical devices and biologic solutions. The firm offers Lapiplasty, a bunion surgery for three-dimensional bunion correction. It operates and distributes its products and services under the following trademarks: Treace Medical Concepts, Lapiplasty, Fast Grafter, Align My Toe, The Future of Hallux Valgus, Fix It Right The First Time, and Plantar Python. The company was founded by John T. Treace in July 2013 and is headquartered in Ponte Vedra Beach, FL.

Employees450
IPOApr 23, 2021
Beta1.55
ATR, 14d0.44
Rel volume2.10
Short float3.73%
Insider own26.71%
Inst own49.14%

Snapshot

6 groups

Valuation

Index-
Market Cap331.73M
Enterprise Value366.41M
Income-55.79M
Sales203.35M
Book/sh0.94
Cash/sh0.61
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees450
IPOApr 23, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S1.63
P/B5.38
P/C8.33
P/FCF-
EV/EBITDA-
EV/Sales1.80
Quick Ratio1.66
Current Ratio2.58
Debt/Eq1.21
LT Debt/Eq1.12
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.86
EPS next Y-0.77
EPS next Q-0.09
EPS this Y12.11%
EPS next Y5.53%
EPS next 5Y9.62%
EPS past 3/5Y-6.38% -61.76%
Sales past 3/5Y14.46% 29.96%
EPS Y/Y TTM-8.36%
Sales Y/Y TTM-7.10%
EPS Q/Q25.12%
Sales Q/Q-3.91%
EarningsNov 06 BMO
EPS/Sales Surpr.25.20% 0.95%

Ownership

Insider Own26.71%
Insider Trans2.50%
Inst Own49.14%
Inst Trans-10.03%
ROA-29.69%
ROE-73.98%
ROIC-42.74%
Gross Margin79.55%
Oper. Margin-24.38%
Profit Margin-27.44%
SMA2015.13%
SMA5014.78%
SMA20052.80%
Trades-

Technical

Shs Outstand65.53M
Shs Float48.05M
Short Float3.73%
Short Ratio6.48
Short Interest1.79M
52W High5.25 -3.62%
52W Low1.17 332.48%
Volatility15.35% 8.91%
ATR (14)0.44
RSI (14)61.88
Beta1.55
Rel Volume2.10
Avg Volume276.46K
Volume579,342

Performance

Perf Week12.44%
Perf Month23.41%
Perf Quarter12.20%
Perf Half Y100.00%
Perf YTD106.53%
Perf Year50.60%
Perf 3Y-18.52%
Perf 5Y-76.37%
Perf 10Y-
Recom2.60
Target Price6.17
Prev Close4.88
Price5.06
Change %3.69%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Nov 09, 2026UpgradeSStifelHold → Buy$4.50 → $6.50+28.5%
Nov 07, 2025DowngradeJJP MorganNeutral → Underweight$5-1.2%
Nov 07, 2025DowngradeBBTIG ResearchBuy → Neutral
Feb 04, 2025UpgradeBBTIG ResearchNeutral → Buy$16+216.2%
Dec 31, 2024InitiatedLLake StreetBuy$14.50+186.6%
Dec 17, 2024ResumedJJP MorganNeutral$8+58.1%
May 16, 2024DowngradeUUBSBuy → Neutral$16 → $6.50+28.5%
May 08, 2024DowngradeTTruistBuy → Hold$17 → $7+38.3%
May 08, 2024DowngradeSStifelBuy → Hold$15 → $6+18.6%
May 08, 2024DowngradeMMorgan StanleyOverweight → Equal-Weight$15 → $5.50+8.7%

Peers

Mkt cap
TickerCompanyMkt cap
KIDSOrthoPediatrics corp879.14M
SIShoulder Innovations Inc458.62M
SIBNSI-BONE Inc1.13B
OFIXOrthofix Medical Inc292.66M
ENOVEnovis Corp1.65B
ATECAlphatec Holdings Inc1.14B
ZBHZimmer Biomet Holdings Inc20.34B
CNMDConmed Corp1.51B
XTNTXtant Medical Holdings Inc38.99M
TNONTenon Medical Inc4.69M

Insider trading

14 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Treace John T.Chief Executive OfficerAug 20 '26Buy4.4439,944177,1767,388,383Aug 24 05:00 PM
Treace John T.Chief Executive OfficerAug 24 '26Buy4.3411,00047,7317,404,383Aug 24 05:00 PM
Treace John T.Chief Executive OfficerAug 21 '26Buy4.355,00021,7487,393,383Aug 24 05:00 PM
Treace John T.Chief Executive OfficerJun 10 '26Buy4.0229,430118,4267,353,263Jun 11 04:52 PM
Treace John T.Chief Executive OfficerJun 11 '26Buy4.0422,88792,5417,376,150Jun 11 04:52 PM
Treace John T.Chief Executive OfficerJun 01 '26Buy3.5650,000177,9157,323,833Jun 01 04:38 PM
Treace John T.Chief Executive OfficerMay 28 '26Buy3.0261,202184,8247,273,833May 28 04:33 PM
Treace John T.Chief Executive OfficerMay 27 '26Buy2.8749,810143,1897,212,631May 28 04:33 PM
Treace John T.Chief Executive OfficerMay 26 '26Buy2.794,50812,5767,162,821May 28 04:33 PM
Treace John T.Chief Executive OfficerMay 14 '26Buy2.6261,750161,4957,158,313May 14 05:33 PM
Treace John T.Chief Executive OfficerMay 13 '26Buy2.4649,013120,5337,096,563May 14 05:33 PM
Treace John T.Chief Executive OfficerMay 12 '26Buy2.1743,00093,4787,047,550May 14 05:33 PM
Scanlan Sean F.Chief Innovation OfficerFeb 10 '26Option Exercise1.0516,87517,719706,474Feb 11 09:00 PM
Scanlan Sean F.Chief Innovation OfficerJan 21 '26Option Exercise0.7253,50038,520427,099Jan 23 09:30 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
IWCiShares Micro-Cap ETFAUM: 1.22B
VHTVanguard Health Care ETFAUM: 21.51B
ITOTiShares Core S&P Total U.S. Stock Market ETFAUM: 95.28B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B
SCHBSchwab U.S. Broad Market ETFAUM: 44.09B
DFMCU.S. Micro Cap Portfolio ETF Class SharesAUM: 212.10M

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-06-0.190-0.254-0.19048.2547.805
2026Q22026-08-07-0.240-0.298-0.24445.3844.025
2026Q12026-05-08-0.280-0.308-0.27847.2045.965
2025Q42026-02-27-0.150-0.152-0.14762.5261.856
2025Q32025-11-06-0.260-0.276-0.25650.2149.836
2025Q22025-08-07-0.280-0.288-0.27647.3947.056
2025Q12025-05-08-0.250-0.302-0.25452.5752.067
2024Q42025-02-27-0.010-0.039-0.00868.7167.257
2024Q32024-11-05-0.250-0.272-0.24745.0943.486
2024Q22024-08-06-0.340-0.291-0.34244.4643.007
2024Q12024-05-07-0.300-0.302-0.30251.1149.077
2023Q42024-02-27-0.100-0.088-0.10262.2160.567
2023Q32023-11-09-0.280-0.264-0.28540.7641.647
2023Q22023-08-08-0.200-0.241-0.20041.9540.846
2023Q12023-05-08-0.230-0.229-0.22942.2039.256
2022Q42023-03-07-0.080-0.139-0.07949.7744.814

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-0.140--0.08457.29-
2021FY-0.430-0.294-0.38394.4293.08
2022FY-0.690-0.817-0.775141.84137.03
2023FY-0.810-0.795-0.814187.12185.27
2024FY-0.900-0.927-0.898209.36207.7
2025FY-0.930-0.938-0.930212.69212.02
2026FY--0.817--207.94
2027FY--0.772--220.72
2028FY--0.687--234.6

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0651167.2666.9068.00
2026Q4S2026-10-2150067.4066.5068.00
2026Q4S2026-10-1351167.4066.5068.00
2026Q4S2026-10-0951167.3066.5068.00
2026Q4S2026-08-1951167.3166.5268.00
2026Q4S2026-08-0751167.3166.5268.00
2026Q4S2026-07-2250067.4065.6068.00
2026Q4S2026-07-1550167.4065.6068.00
2026Q4S2026-07-1050167.4365.6068.15
2026Q4S2026-06-0950167.4365.6168.15
2026Q4S2026-05-1350167.4365.6068.15
2026Q4S2026-05-1151167.4365.6068.15
2026Q4S2026-05-0851167.4065.6068.00
2026Q4S2026-04-0852067.8667.5068.00

Estimate history

EPS, annual-0.096-0.084-0.383-0.775-0.814-0.898-0.933-0.8611
Period2019202020212022202320242025TTM
EPS, quarterly-0.247-0.008-0.254-0.276-0.256-0.147-0.278-0.244-0.192
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual39.41657.36594.419141.838187.118209.357212.69203.35
Period2019202020212022202320242025TTM
Sales, quarterly45.08668.70852.5747.38750.21462.51947.19845.37648.253
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual51.16651.16654.18155.62861.7562.36263.86465.526
Period2019202020212022202320242025MRQ
Shares, quarterly62.27562.36262.89263.04263.70563.86464.78665.23665.526
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue203.35212.69209.36187.12141.8494.4257.3739.42
Cost of Goods Sold Incl. D&A41.5842.9441.0935.1827.5217.8312.477.63
Gross Profit161.76169.75168.26151.94114.3176.5944.9031.79
Selling, General and Administrative Excl. Other211.34223.91223.95203.37149.1693.1044.0435.32
Research and Development18.0320.2820.5915.4413.5810.205.855.07
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-49.58-54.15-55.69-51.43-34.84-16.510.85-3.54
Interest Expense6.075.325.265.174.404.062.780.84
Unusual Expense2.742.740.050.164.31-0.070.000.00
Net Income Before Taxes-55.79-59.00-55.74-49.53-42.81-20.55-3.67-4.26
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-55.79-59.00-55.74-49.53-42.81-20.55-3.67-4.26
Net Income From Continuing Operations-55.79-59.00-55.74-49.53-42.81-20.55-3.67-4.26
Net Income-55.79-59.00-55.74-49.53-42.81-20.75-4.31-4.91
EPS (Recurring)-0.82-0.90-0.90-0.81-0.72-0.38-0.08-0.10
EPS (Basic, Before Extraordinaries)-0.86-0.93-0.90-0.81-0.77-0.38-0.08-0.10
EPS (Diluted)-0.86-0.93-0.90-0.81-0.77-0.38-0.08-0.10
EBITDA-41.85-43.53-47.27-46.08-30.19-15.822.06-2.74
Non-Operating Income (Expense)2.593.215.257.230.74-0.05-1.750.11
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense28.9833.8230.6017.358.113.410.920.81
Price To Sales Ratio1.430.732.214.158.9610.70--
Gross Margin79.5579.8180.3781.2080.6081.1278.2680.64
Operating Margin-24.38-25.46-26.60-27.48-24.57-17.491.49-8.97
Net Margin-27.44-27.74-26.63-26.47-30.19-21.97-7.51-12.44
Shares Outstanding65.5363.8662.3661.7555.6354.1851.1751.17
Market Capitalization319.93319.93463.49786.371,275.98991.14984.76-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue48.2545.3847.2062.5250.2147.3952.5768.71
Cost of Goods Sold Incl. D&A9.909.779.7912.1210.519.6310.6813.23
Gross Profit38.3535.6137.4150.4039.7137.7541.8955.48
Selling, General and Administrative Excl. Other49.8850.5654.5756.3255.3854.7357.4855.68
Research and Development4.494.384.624.544.685.505.565.21
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-11.53-14.96-17.17-5.92-15.68-16.97-15.58-0.20
Interest Expense1.581.561.571.351.341.321.311.31
Unusual Expense0.000.000.002.740.000.000.000.05
Net Income Before Taxes-12.57-15.87-17.96-9.39-16.29-17.40-15.92-0.50
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-12.57-15.87-17.96-9.39-16.29-17.40-15.92-0.50
Net Income From Continuing Operations-12.57-15.87-17.96-9.39-16.29-17.40-15.92-0.50
Net Income-12.57-15.87-17.96-9.39-16.29-17.40-15.92-0.50
EPS (Recurring)-0.19-0.24-0.28-0.12-0.26-0.28-0.25-0.01
EPS (Basic, Before Extraordinaries)-0.19-0.24-0.28-0.15-0.26-0.28-0.25-0.01
EPS (Diluted)-0.19-0.24-0.28-0.15-0.26-0.28-0.25-0.01
EBITDA-9.50-12.97-16.27-3.11-12.90-14.40-13.122.03
Non-Operating Income (Expense)0.550.650.780.610.730.900.971.07
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense6.936.468.037.558.009.588.698.55
Price To Sales Ratio1.431.260.420.741.951.732.492.22
Gross Margin79.4878.4779.2680.6279.0779.6779.6980.74
Operating Margin-23.90-32.96-36.37-9.47-31.22-35.82-29.64-0.30
Net Margin-26.04-34.98-38.05-15.03-32.44-36.71-30.29-0.73
Shares Outstanding65.5365.2464.7963.8663.7063.0462.8962.36
Market Capitalization319.93258.1986.55156.11423.89369.88525.37463.49

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments48.3775.68123.2081.25105.8318.0812.14
Short Term Receivables42.4540.8038.0629.2018.5714.4910.41
Inventories36.0339.2629.2519.3310.567.825.56
Other Current Assets5.205.677.853.623.010.590.46
Total Current Assets132.05161.40198.36133.40137.9740.9828.57
Net Property, Plant & Equipment37.3734.4031.5625.482.850.831.15
Total Investments and Advances0.000.000.000.000.000.000.00
Intangible Assets19.9420.8921.84-0.000.000.00
Other Assets1.220.410.150.150.000.000.00
Total Assets190.58217.09251.91159.02140.8241.8129.72
Short Term Debt Incl. Current Port. of LT Debt2.300.411.400.340.001.790.00
Accounts Payable6.7310.5211.848.674.062.270.93
Other Current Liabilities21.6123.9931.7921.2414.157.546.40
Total Current Liabilities30.6434.9245.0330.2518.2111.607.33
Long Term Debt69.5669.2468.9068.2529.3629.1919.22
Provision for Risks Charges0.000.000.000.000.000.000.00
Other Liabilities3.050.040.040.000.170.240.00
Total Liabilities103.25104.20113.9798.5047.7541.0326.55
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.007.937.93
Common Equity87.33112.89137.9460.5393.07-7.16-4.77
Total Shareholders Equity87.33112.89137.9460.5393.070.783.16
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity87.33112.89137.9460.5393.070.783.16
Total Liabilities & Stockholders Equity190.58217.09251.91159.02140.8241.8129.72
Book Value Per Share1.371.812.231.091.72-0.14-0.09
Tangible Book Value Per Share1.061.481.881.091.72-0.14-0.09
Full-Time Employees450477516423248133-
Price to Book Ratio5.194.425.7020.5110.8510.04-
Return on Assets-28.95-23.77-24.10-28.56-22.51-10.26-
Return on Equity-58.94-44.45-49.91-55.75-43.80-186.33-
Return on Invested Capital-37.61-30.61-23.94-33.25-16.79-12.24-19.05
Quick Ratio3.133.503.763.777.002.863.14
Current Ratio4.314.624.404.417.583.533.90

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-55.79-59.00-55.74-49.53-42.81-20.55-3.67-4.26
Depreciation7.6310.628.425.354.660.691.210.79
Other Funds (Non Cash)37.6240.9935.5919.3413.324.003.281.11
Funds from Operations-10.55-7.39-11.73-24.83-24.84-15.860.82-2.37
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital1.80-8.58-25.43-9.74-5.81-1.33-5.32-5.31
Cash from Operating Activities-8.74-15.97-37.17-34.58-30.65-17.19-4.50-7.67
Capital Expenditures-9.83-13.52-11.59-11.46-14.84-2.71-1.07-1.21
Net Assets From Acquisitions0.000.000.00-20.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00
Purchase or Sale of Investments17.4926.7746.97-49.84-61.680.000.000.00
Purchase of Investments-31.86-40.57-71.58-169.87-63.410.000.000.00
Sale Or Maturity of Investments49.3567.34118.55120.021.730.000.000.00
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities7.6613.2535.38-81.30-76.52-2.71-1.07-1.21
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock0.180.550.43109.402.19109.440.360.07
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.180.550.43109.402.19109.440.360.07
Proceedsfrom Stock Options0.000.000.00107.530.00107.610.000.00
Issuance or Reduction of Debt, Net1.702.430.000.0018.62-1.7911.1419.67
Change in Long Term Debt1.801.800.000.0018.62-1.799.3519.67
Issuance of Long Term Debt58.1158.110.000.0052.510.0029.3519.67
Reduction of Long Term Debt-56.31-56.310.000.00-33.89-1.79-20.000.00
Net Financing Active Other Cash Flow-0.72-0.90-0.27-0.010.000.000.000.00
Other Financing Activities Uses-0.72-0.90-0.27-0.010.000.000.000.00
Cash from Financing Activities1.162.080.16109.3820.81107.6511.5019.74
Net Change in Cash0.07-0.64-1.63-6.49-86.3687.755.9410.86
Free Cash Flow-18.58-29.49-48.76-46.03-45.49-19.90-5.56-8.88
Preferred Dividends (Cash Flow)-0.000.000.000.00---
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments39.8045.6251.8548.3757.4269.29
Short Term Receivables30.5229.0330.7642.4533.5630.93
Inventories42.3039.5436.3736.0341.4242.40
Other Current Assets6.076.264.495.205.604.98
Total Current Assets118.69120.45123.47132.05138.00147.60
Net Property, Plant & Equipment39.9539.6339.4337.3737.8037.75
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets19.2319.4619.7019.9420.1820.41
Other Assets1.431.501.501.220.610.68
Total Assets179.30181.06184.10190.58196.59206.44
Short Term Debt Incl. Current Port. of LT Debt5.603.922.232.303.913.20
Accounts Payable14.2816.0613.546.7316.1019.96
Other Current Liabilities26.2021.5218.7221.6120.8918.74
Total Current Liabilities46.0841.5034.4930.6440.9141.90
Long Term Debt68.8969.1369.3769.5666.4666.89
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities2.692.693.053.050.040.04
Total Liabilities117.65113.32106.91103.25107.40108.83
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity61.6567.7477.1987.3389.1997.61
Total Shareholders Equity61.6567.7477.1987.3389.1997.61
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity61.6567.7477.1987.3389.1997.61
Total Liabilities & Stockholders Equity179.30181.06184.10190.58196.59206.44
Book Value Per Share0.941.041.191.371.401.55
Tangible Book Value Per Share0.650.740.891.061.081.22
Full-Time Employees---450--
Price to Book Ratio5.193.340.981.754.333.51
Return on Assets-29.69-30.72-31.31-28.95-24.47-22.74
Return on Equity-73.98-71.99-66.88-58.94-51.63-46.89
Return on Invested Capital-9.63-11.60-12.25-5.99-10.46-10.58
Quick Ratio1.661.952.533.132.362.51
Current Ratio2.582.903.584.313.373.52

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-12.57-15.87-17.96-9.39-16.29-17.40
Depreciation2.031.890.902.812.782.58
Other Funds (Non Cash)8.218.179.5611.679.0910.28
Funds from Operations-2.32-5.81-7.505.08-4.42-4.54
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.941.1214.73-13.11-4.671.49
Cash from Operating Activities-3.25-4.707.23-8.03-9.09-3.05
Capital Expenditures-2.17-2.20-3.06-2.40-2.81-4.77
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.919.27-4.7512.0611.541.51
Purchase of Investments-7.51-2.60-16.07-5.68-4.64-15.16
Sale Or Maturity of Investments8.4211.8711.3217.7516.1816.67
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-1.267.07-7.829.678.74-3.26
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.010.010.090.070.240.12
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.010.010.090.070.240.12
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.070.71-0.471.390.160.89
Change in Long Term Debt0.000.000.001.800.000.00
Issuance of Long Term Debt0.000.000.0058.110.000.00
Reduction of Long Term Debt0.000.000.00-56.310.000.00
Net Financing Active Other Cash Flow-0.41-0.03-0.21-0.07-0.41-0.01
Other Financing Activities Uses-0.41-0.03-0.21-0.07-0.41-0.01
Cash from Financing Activities-0.340.70-0.581.38-0.010.99
Net Change in Cash-4.853.07-1.163.02-0.37-5.32
Free Cash Flow-5.43-6.904.17-10.42-11.90-7.82

Revenue breakdown

Surgical & Medical Instruments & Apparatus2024: 209.36M 2025: 212.69M
United States2024: 209.36M 2025: 212.69M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-303.76%1.8M47.7M284.14K
2026-10-154.04%1.9M47.7M303.57K
2026-09-304.15%2.0M47.7M350.23K
2026-09-153.65%1.7M47.6M586.19K
2026-08-313.28%1.6M47.6M670.46K
2026-08-143.31%1.6M48.2M725.80K
2026-07-313.53%1.7M48.1M725.44K
2026-07-153.84%1.8M48.1M751.96K
2026-06-303.64%1.7M48.1M914.49K
2026-06-156.80%3.3M48.1M721.41K
2026-05-298.54%4.1M48.1M809.55K
2026-05-157.48%3.6M48.3M835.57K
2026-04-308.08%4.0M49.1M865.54K
2026-04-159.84%4.8M49.1M882.62K
2026-03-319.84%4.4M44.8M754.30K
2026-03-138.89%4.0M44.8M852.45K
2026-02-278.18%3.7M44.8M755.04K
2026-02-138.05%3.6M44.2M783.01K
2026-01-307.31%3.2M44.4M908.54K
2026-01-156.58%3.0M45.7M850.48K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.502.053.001.926.2221000.000.912-0.0320.001
call5.000.200.600.351.8233801100.588-0.0420.003
call7.500.000.750.004.0050.000.000.375-0.0680.003
put2.500.000.200.004.5300.000.00-0.088-0.0320.001
put5.000.050.851.012.85048.000.00-0.412-0.0410.003
put7.501.953.402.605.2000.001.00-0.625-0.0670.003

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-068-KCurrent report2026-11-06SEC
2026-10-284Statement of changes in beneficial ownership of securities2026-10-24SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-08-244Statement of changes in beneficial ownership of securities2026-08-20SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-124Statement of changes in beneficial ownership of securities2026-08-09SEC
2026-08-12SCHEDULE 13G/ASEC
2026-08-124Statement of changes in beneficial ownership of securities2026-08-09SEC
2026-08-124Statement of changes in beneficial ownership of securities2026-08-09SEC
2026-08-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-078-KCurrent report2026-08-07SEC
2026-07-30SCHEDULE 13G/ASEC
2026-06-124/A2026-06-10SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-014Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-05-284Statement of changes in beneficial ownership of securities2026-05-26SEC
2026-05-208-KCurrent report2026-05-19SEC
2026-05-194Statement of changes in beneficial ownership of securities2026-05-19SEC
2026-05-194Statement of changes in beneficial ownership of securities2026-05-19SEC
2026-05-194Statement of changes in beneficial ownership of securities2026-05-19SEC
2026-05-194Statement of changes in beneficial ownership of securities2026-05-19SEC
2026-05-194Statement of changes in beneficial ownership of securities2026-05-19SEC
2026-05-194Statement of changes in beneficial ownership of securities2026-05-19SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-144Statement of changes in beneficial ownership of securities2026-05-12SEC
2026-05-14SCHEDULE 13GSEC
2026-05-08S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-05-0810-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-088-KCurrent report2026-05-08SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-08246.65K300
2026-070000
2026-06388.88K300
2026-05716.09K600
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
ARMISTICE CAPITAL, LLC9.81%
GAGNON SECURITIES LLC5.25%
BANK OF AMERICA CORP /DE/5.09%
VANGUARD CAPITAL MANAGEMENT LLC3.13%
Gagnon Advisors, LLC2.36%
AQR CAPITAL MANAGEMENT LLC2.31%
BlackRock, Inc.2.13%
ACADIAN ASSET MANAGEMENT LLC2.08%
MARSHALL WACE, LLP2.05%
CIBC Bancorp USA Inc.1.87%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.23%
VANGUARD EXTENDED MARKET INDEX FUND0.84%
Fidelity Small Cap Index Fund0.74%
Fidelity Extended Market Index Fund0.39%
VANGUARD RUSSELL 2000 INDEX FUND0.38%
Schwab U.S. Small-Cap ETF0.35%
iShares Micro-Cap ETF0.26%
VANGUARD HEALTH CARE INDEX FUND0.24%
Schwab Small-Cap Index Fund0.17%
Fidelity Total Market Index Fund0.14%

OakChart. TMCI. Cached 15 minutes.